Literature DB >> 15686303

Omalizumab (Xolair) for treatment of asthma.

Liya Davydov1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15686303

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN： 0002-838X            Impact factor:   3.292


× No keyword cloud information.
  4 in total

Review 1.  Tumor necrosis factor inhibitors for the treatment of asthma.

Authors:  Jiyoun Kim; Daniel G Remick
Journal:  Curr Allergy Asthma Rep       Date:  2007-05       Impact factor: 4.806

Review 2.  Therapeutic Strategies of Biologics in Chronic Rhinosinusitis: Current Options and Future Targets.

Authors:  Junhu Tai; Munsoo Han; Tae Hoon Kim
Journal:  Int J Mol Sci       Date:  2022-05-15       Impact factor: 6.208

3.  Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model.

Authors:  Ann C Wu; A David Paltiel; Karen M Kuntz; Scott T Weiss; Anne L Fuhlbrigge
Journal:  J Allergy Clin Immunol       Date:  2007-09-29       Impact factor: 10.793

4.  Blocking of Histamine Release and IgE Binding to FcεRI on Human Basophils by Antibodies Produced in Camels.

Authors:  Al Qaoud Khaled; Yousef Sana; Rawashdeh Abdulrahman; Khalil Raida; Abdel Hafez Sami
Journal:  Allergy Asthma Immunol Res       Date:  2015-06-25       Impact factor: 5.764
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.